X0306 4 2020-03-12 0 0001672619 IMARA Inc. IMRA 0001572451 Bonita David P C/O IMARA INC., 116 HUNTINGTON AVE, 6TH FLOOR BOSTON MA 02116 1 0 1 0 Common Stock 2020-03-12 4 P 0 937500 16.00 A 937500 I By OrbiMed Private Investments VII, LP Common Stock 2020-03-16 4 C 0 1594902 A 2532402 I By OrbiMed Private Investments VII, LP Series B Preferred Stock 2020-03-16 4 C 0 10046294 0.00 D Common Stock 1594902 0 I By OrbiMed Private Investments VII, LP Stock Option (right to buy) 16.00 2020-03-16 4 A 0 15457 0.00 A 2030-03-15 Common Stock 15457 15457 D On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. The securities are held by OrbiMed Private Investments VII, LP, or OPI VII. OrbiMed Capital GP VII LLC, or GP VII, is general partner of OPI VII, and OrbiMed Advisors LLC, or Advisors, is the managing member of GP VII. The Reporting Person is a member of Advisors. By virtue of such relationships, GP VII and Advisors may be deemed to have voting and investment power with respect to the shares held by OPI VII. Both GP VII and Advisors may be deemed to directly or indirectly, including by reason of their mutual affiliation, to be the beneficial owners of the shares held by OPI VII. Advisors exercises investment and voting power through a management committee comprised of Carl L. Gordon, Jonathan T. Silverstein, and Sven H. Borho, each of whom disclaims beneficial ownership of the shares held by OPI VII. The Reporting Person disclaims beneficial ownership of the securities reported herein for purposes of Rule 16a-1(a) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), except to the extent of its pecuniary interest therein, if any. This report shall not be deemed an admission that any such entity or person is a beneficial owner of such securities for purpose of Section 16 of the Exchange Act, or for any other purpose. The option vests in three equal installments on March 16, 2021, 2022 and 2023. Pursuant to an agreement with Advisors and GP VII, the Reporting Person is obligated to transfer these securities, or the economic benefit thereof, to Advisors and GP VII, which will in turn ensure that such securities or economic benefits are provided to OPI VII. /s/ Michael P. Gray, Attorney-in-Fact 2020-03-16